- Stocks
- Healthcare
- NASDAQ: AMPH

Price (delayed)

$20.86

Market cap

$993.67M

P/E Ratio

347.67

Dividend/share

N/A

EPS

$0.06

Enterprise value

$956.51M

Amphastar Pharmaceuticals's revenue has increased by 13% YoY and by 5% QoQ

The company's gross profit rose by 10% YoY and by 6% QoQ

The EPS has soared by 100% from the previous quarter but it has plunged by 95% YoY

The net income has plunged by 95% YoY but it has soared by 78% from the previous quarter

The stock's P/E is 4.9% more than its last 4 quarters average of 331.3

Amphastar Pharmaceuticals's gross margin has decreased by 2.4% YoY

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.amphastar.com

Peers:
MRNS

What are the main financial stats of AMPH

Market
Valuations
Earnings

Shares outstanding

47.64M

Market cap

$993.67M

Enterprise value

$956.51M

Price to earnings (P/E)

347.67

Price to book (P/B)

2.44

Price to sales (P/S)

2.69

EV/EBIT

180.07

EV/EBITDA

35.73

EV/Sales

2.6

Revenue

$368.18M

EBIT

$5.31M

EBITDA

$26.77M

Free cash flow

$45.15M

Per share
Balance sheet
Liquidity

EPS

$0.06

Free cash flow per share

$0.95

Book value per share

$8.55

Revenue per share

$7.75

TBVPS

$12.74

Total assets

$645.74M

Total liabilities

$194.78M

Debt

$64.67M

Equity

$405.56M

Working capital

$173.07M

Debt to equity

0.16

Current ratio

2.36

Quick ratio

1.54

Net debt/EBITDA

-1.39

Margins
Efficiency
Dividend

EBITDA margin

7.3%

Gross margin

41.1%

Net margin

0.7%

Operating margin

3.7%

Return on assets

0.4%

Return on equity

0.6%

Return on invested capital

1.2%

Return on capital employed

1%

Return on sales

1.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Amphastar Pharmaceuticals stock price performed over time

Intraday

2.2%

1 week

3.99%

1 month

2.71%

1 year

2.31%

YTD

3.73%

QTD

3.47%

How have Amphastar Pharmaceuticals's revenue and profit performed over time

Revenue

$368.18M

Gross profit

$151.46M

Operating income

$13.78M

Net income

$2.5M

Gross margin

41.1%

Net margin

0.7%

AMPH's net margin has dropped by 96% year-on-year but it has surged by 75% since the previous quarter

The net income has plunged by 95% YoY but it has soared by 78% from the previous quarter

The operating income has increased by 30% year-on-year and by 26% since the previous quarter

AMPH's operating margin is up by 19% since the previous quarter and by 16% year-on-year

What is Amphastar Pharmaceuticals's growth rate over time

What is Amphastar Pharmaceuticals stock price valuation

P/E

347.67

P/B

2.44

P/S

2.69

EV/EBIT

180.07

EV/EBITDA

35.73

EV/Sales

2.6

The EPS has soared by 100% from the previous quarter but it has plunged by 95% YoY

The stock's P/E is 4.9% more than its last 4 quarters average of 331.3

Amphastar Pharmaceuticals's equity has increased by 7% YoY

The price to book (P/B) is 6% higher than the last 4 quarters average of 2.3 but 2.4% lower than the 5-year quarterly average of 2.5

Amphastar Pharmaceuticals's revenue has increased by 13% YoY and by 5% QoQ

AMPH's price to sales (P/S) is 10% less than its 5-year quarterly average of 3.0

How efficient is Amphastar Pharmaceuticals business performance

The company's return on assets has surged by 100% QoQ but it has shrunk by 96% YoY

The ROE has plunged by 96% YoY but it has soared by 50% from the previous quarter

The ROS has plunged by 93% YoY and by 7% from the previous quarter

The ROIC has dropped by 93% year-on-year

What is AMPH's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for AMPH.

How did Amphastar Pharmaceuticals financials performed over time

AMPH's total liabilities is up by 30% year-on-year and by 7% since the previous quarter

Amphastar Pharmaceuticals's current ratio has decreased by 20% YoY and by 5% from the previous quarter

AMPH's debt is 84% smaller than its equity

Amphastar Pharmaceuticals's debt to equity has decreased by 11% YoY and by 6% from the previous quarter

Amphastar Pharmaceuticals's equity has increased by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.